Displaying 101 - 150 of 170 results
Released Company Title Industry Topic
12 May 2022
10:50 CEST
NYKODE THERAPEUTICS AS Nykode Therapeutics AS - Minutes of Annual General Meeting 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
11 May 2022
19:12 CEST
NYKODE THERAPEUTICS AS Financial calendar 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
09 May 2022
06:45 CEST
NYKODE THERAPEUTICS AS Nykode Therapeutics announces positive interim results from its Phase 2 trial with VB10.16 in combination with immune checkpoint inhibitor atezolizumab in advanced cervical cancer 20103010 Biotechnology Inside information
06 May 2022
12:45 CEST
NYKODE THERAPEUTICS AS Nykode Therapeutics – Invitation to Capital Markets Day in Oslo on May 12, 2022 20103010 Biotechnology Non-regulatory press releases
05 May 2022
08:00 CEST
NYKODE THERAPEUTICS AS Nykode Therapeutics AS - Notice of Annual General Meeting 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
19 Apr 2022
08:30 CEST
NYKODE THERAPEUTICS AS Nykode Therapeutics to host Capital Markets Day 20103010 Biotechnology Non-regulatory press releases
19 Apr 2022
08:00 CEST
NYKODE THERAPEUTICS AS Nykode Therapeutics to present at Kempen Life Sciences Conference 20103010 Biotechnology Non-regulatory press releases
08 Apr 2022
19:00 CEST
NYKODE THERAPEUTICS AS Nykode Therapeutics announces presentation of preclinical data from its second generation Vaccibody vaccine technology at 2022 American Association for Cancer Research (AACR) Annual Meeting 20103010 Biotechnology Non-regulatory press releases
08 Apr 2022
15:35 CEST
NYKODE THERAPEUTICS AS Registration of new share capital 20103010 Biotechnology Total number of voting rights and capital
01 Apr 2022
07:00 CEST
NYKODE THERAPEUTICS AS Nykode Therapeutics - full year 2021 financial results and corporate presentation 20103010 Biotechnology Non-regulatory press releases
31 Mar 2022
23:30 CEST
NYKODE THERAPEUTICS AS Mandatory notification of exercise of warrants and sale of shares to primary insider’s related party 20103010 Biotechnology Mandatory notification of trade primary insiders
31 Mar 2022
19:00 CEST
NYKODE THERAPEUTICS AS Nykode Therapeutics reports full year 2021 financial results 20103010 Biotechnology Annual financial and audit Reports
28 Mar 2022
08:00 CEST
NYKODE THERAPEUTICS AS Nykode to announce full year 2021 financial results on March 31, 2022 and host webcast presentation on April 1, 2022 20103010 Biotechnology Non-regulatory press releases
08 Mar 2022
22:30 CET
NYKODE THERAPEUTICS AS Nykode Therapeutics to Present at 2022 American Association for Cancer Research (AACR) Annual Meeting 20103010 Biotechnology Non-regulatory press releases
01 Mar 2022
15:11 CET
NYKODE THERAPEUTICS AS Share capital increase from exercise of warrants 20103010 Biotechnology Total number of voting rights and capital
22 Feb 2022
12:30 CET
NYKODE THERAPEUTICS AS Mandatory notification of acquisition of shares by primary insider 20103010 Biotechnology Mandatory notification of trade primary insiders
15 Feb 2022
15:04 CET
NYKODE THERAPEUTICS AS Mandatory notification of exercise of warrants 20103010 Biotechnology Mandatory notification of trade primary insiders
14 Feb 2022
06:45 CET
NYKODE THERAPEUTICS AS Nykode Therapeutics to Present at SVB Leerink 2022 Global Healthcare Conference 20103010 Biotechnology Non-regulatory press releases
11 Feb 2022
06:45 CET
NYKODE THERAPEUTICS AS Nykode Therapeutics announces completion of patient enrollment in its Phase 2 trial of VB10.16 in combination with atezolizumab for the treatment of advanced cervical cancer 20103010 Biotechnology Non-regulatory press releases
30 Dec 2021
17:31 CET
NYKODE THERAPEUTICS AS Financial calendar 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
28 Dec 2021
06:45 CET
NYKODE THERAPEUTICS AS Nykode Therapeutics announces first subject dosed with its T cell focused next-generation SARS-CoV-2 vaccine candidate 20103010 Biotechnology Non-regulatory press releases
22 Dec 2021
11:30 CET
NYKODE THERAPEUTICS AS Minutes of Extraordinary General Meeting 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
20 Dec 2021
16:58 CET
NYKODE THERAPEUTICS AS Nykode Therapeutics AS - Mandatory notification of purchase by related party to primary insider 20103010 Biotechnology Mandatory notification of trade primary insiders
20 Dec 2021
16:33 CET
NYKODE THERAPEUTICS AS Share capital increase from exercise of warrants 20103010 Biotechnology Total number of voting rights and capital
15 Dec 2021
09:24 CET
VACCIBODY Nykode Therapeutics AS - New name registered 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
15 Dec 2021
08:26 CET
VACCIBODY Vaccibody AS*) – Notice of Extraordinary General Meeting 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
15 Dec 2021
08:25 CET
VACCIBODY New chairman at Nykode Therapeutics as the Company enters a new stage of internationalization 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
09 Dec 2021
17:49 CET
VACCIBODY Registration of new share capital 20103010 Biotechnology Total number of voting rights and capital
03 Dec 2021
17:26 CET
VACCIBODY Mandatory notification of trade by primary insiders and related parties 20103010 Biotechnology Mandatory notification of trade primary insiders
03 Dec 2021
16:49 CET
VACCIBODY Subscription of warrants 20103010 Biotechnology Mandatory notification of trade primary insiders
30 Nov 2021
13:30 CET
VACCIBODY Minutes of Extraordinary General Meeting 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
24 Nov 2021
16:35 CET
VACCIBODY Nykode Therapeutics (formerly Vaccibody*)) resolves to issue shares to Regeneron 20103010 Biotechnology Total number of voting rights and capital
23 Nov 2021
06:47 CET
VACCIBODY Nykode Therapeutics (formerly Vaccibody*)) enters into multi-target license and collaboration agreement with Regeneron to develop innovative vaccines against cancer and infectious diseases 20103010 Biotechnology Non-regulatory press releases
23 Nov 2021
06:46 CET
VACCIBODY Vaccibody AS – Notice of Extraordinary General Meeting 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
23 Nov 2021
06:45 CET
VACCIBODY Vaccibody becomes Nykode Therapeutics - a new name and identity to signify a new phase of growth and development 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
17 Nov 2021
07:00 CET
VACCIBODY Vaccibody AS - Quarterly report Q3 2021 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
10 Nov 2021
08:00 CET
VACCIBODY Vaccibody to participate at Jefferies London Healthcare Conference 20103010 Biotechnology Non-regulatory press releases
03 Nov 2021
16:30 CET
VACCIBODY Vaccibody announces first subject dosed in a two-arm phase 1/2 clinical trial with next-generation SARS-CoV-2 vaccine candidates 20103010 Biotechnology Non-regulatory press releases
02 Nov 2021
16:39 CET
VACCIBODY Mandatory notification of intra group transfer of shares by primary insider’s related party 20103010 Biotechnology Mandatory notification of trade primary insiders
01 Nov 2021
17:00 CET
VACCIBODY Registration of new share capital 20103010 Biotechnology Total number of voting rights and capital
29 Oct 2021
08:00 CEST
VACCIBODY Share capital increase from exercise of warrants 20103010 Biotechnology Total number of voting rights and capital
14 Oct 2021
08:00 CEST
VACCIBODY Mandatory notification of intra group transfer of shares by primary insider’s related party 20103010 Biotechnology Mandatory notification of trade primary insiders
12 Oct 2021
18:18 CEST
VACCIBODY Mandatory notification of intra group transfer of shares by primary insider’s related party 20103010 Biotechnology Mandatory notification of trade primary insiders
04 Oct 2021
08:00 CEST
VACCIBODY Vaccibody to participate at Guggenheim Securities’ 2nd Annual Vaccine and Infectious Disease Days 20103010 Biotechnology Non-regulatory press releases
30 Sep 2021
17:04 CEST
VACCIBODY Resolution to issue shares as a consequence of option exercise 20103010 Biotechnology Total number of voting rights and capital
24 Sep 2021
16:40 CEST
VACCIBODY Mandatory notification of transfer of shares by primary insider to closely associated person 20103010 Biotechnology Mandatory notification of trade primary insiders
20 Sep 2021
16:54 CEST
VACCIBODY Vaccibody AS - Mandatory notification of intra group transfer of shares by primary insider’s related party 20103010 Biotechnology Mandatory notification of trade primary insiders
10 Sep 2021
17:06 CEST
VACCIBODY Vaccibody AS - Mandatory notification of intra group transfer of shares by primary insider’s related party 20103010 Biotechnology Mandatory notification of trade primary insiders
07 Sep 2021
18:04 CEST
VACCIBODY Share capital increase from exercise of warrants 20103010 Biotechnology Total number of voting rights and capital
26 Aug 2021
06:30 CEST
VACCIBODY Vaccibody AS - Quarterly report Q2 2021 20103010 Biotechnology Half yearly financial reports and audit reports/limited reviews